2023 World Conference on Lung Cancer (Posters)-EP07.02. Adjuvant Chemotherapy with Nanoparticle Albumin-Bound Paclitaxel and Carboplatin for Stage IB Non-small Cell Lung Cancer

EP07.02. Adjuvant Chemotherapy with Nanoparticle Albumin-Bound Paclitaxel and Carboplatin for Stage IB Non-small Cell Lung Cancer - PDF(Slides)

Back to course

Pdf Summary

This study aimed to evaluate the feasibility and safety of adjuvant chemotherapy (AC) using nanoparticle albumin-bound paclitaxel (nab-PTX) and carboplatin (CBDCA) in patients with stage IB non-small cell lung cancer (NSCLC) following surgical resection. The primary endpoint was the completion rate of chemotherapy, and the secondary endpoints were overall survival (OS), relapse-free survival (RFS), and safety. The target completion rate was set at 80% based on the results of previous tests.<br /><br />The inclusion criteria for the study were patients with pathologically confirmed NSCLC stage IB, complete resection, and no prior treatment other than surgery. The major organ functions needed to be maintained within normal limits, and patients had to have a performance status of 0 or 1. The exclusion criteria included hypersensitivity to the drugs, interstitial pneumonia, active multiple cancers, and serious complications.<br /><br />The chemotherapy regimen consisted of nab-PTX/CBDCA combination therapy, and treatment was initiated within 8 weeks after surgery. A total of 4 courses of chemotherapy were given. The study enrolled 35 patients, and the completion rate was 75.8%.<br /><br />The results showed that the frequency of hematologic toxicities, particularly leukopenia and neutropenia, was high, with incidence rates over 90%. Severe neutropenia (Grade 3 or higher) was observed in 79.4% of patients. Other side effects such as anorexia, nausea, and alopecia were observed but had low rates of severe side effects.<br /><br />The completion rate of the AC with nab-PTX and CBDCA was lower than expected due to the high incidence of neutropenia. However, the prognosis for stage IB lung cancer was favorable once the side effects were managed.<br /><br />In conclusion, AC using nab-PTX and CBDCA for stage IB NSCLC showed high rates of hematologic toxicities, leading to a lower completion rate. However, the prognosis was favorable for these patients once the side effects were overcome. Further research is needed to optimize the chemotherapy regimen for Japanese patients.

Asset Subtitle

Yamato Motooka

Meta Tag

Speaker Yamato Motooka

Topic Early-Stage NSCLC: New Technology & Innovations

Keywords

adjuvant chemotherapy

nanoparticle albumin-bound paclitaxel

carboplatin

stage IB non-small cell lung cancer

surgical resection

completion rate

overall survival

relapse-free survival

safety

chemotherapy regimen